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Summary
Growth failure is a psychosocial problem for many patients who
have undergone renal transplantation.
18 adolescents (mean age 15 6, range 11&middot;3-19 5) with
severe growth retardation after renal transplantation were
treated with biosynthetic growth hormone (GH) for 2 years. All
received prednisone, administered daily or on alternate days,
with azathioprine and/or cyclosporin A. 16 were blindly
assigned to one of two GH doses (4 vs 8 IU per m2 per day).
Growth, bone maturation, renal graft function, plasma insulin-
like growth factors, serum binding proteins, and other
biochemical parameters were checked regularly. Glomerular
filtration rate and effective renal plasma flow were tested with
125I-Thalamate and 131I-Hippuran. Data on growth and
glomerular filtration rate during GH treatment were also
compared with those of matched non-GH-treated controls.
Mean (standard deviation) increment in height after 2 years of
GH was 15&middot;7 (5&middot;1) cm, significantly greater (p<0 0001)
than in matched controls, 5 8 (3 4) cm. Results were similar
for the two GH dosage groups. Bone maturation was not
accelerated. Glomerular filtration rate and effective renal
plasma flow did not change significantly. The incidence of a
>25% reduction in glomerular filtration rate over 2 years was
not significantly higher in GH-treated patients than in non-GH-
treated controls (39% vs 32%, p=0&middot;97). Although a few
patients had deterioration of graft function, we could not find a
relation with GH treatment.
Our results show that sustained improvement of height can
be achieved with GH in severely growth-retarded adolescents
after renal transplantation.
Lancet 1994; 343: 1313-17
Introduction
Adult height remains below the 3rd percentile for
approximately 75% of patients undergoing renal
transplantation (RTx) before the age of 15 yr.’ Much of the
growth retardation occurs before RTx and the rate of
growth may improve after RTx, but this improvement is
rarely sustained.2,3 Poor growth before RTx has a
significant negative influence on adult height, but the loss
of growth potential during puberty also seems important.4
Why growth retardation should persist after RTx is not
known. Children with post-RTx growth retardation
appeared to have significantly lower mean plasma growth
hormone (GH) concentrations during 24 h profile testing
than healthy controls, regardless of pubertal stage.5 Plasma
insulin-like growth factors (IGF-I and -II) were within the
normal range 3’ but serum IGF-binding protein-3
(IGFBP-3) were above normal in all growth-retarded RTx
recipients.5 Growth retardation after RTx may be the result
of inhibitory effects of prednisone treatment on GH
secretion as well as to decreased IGF-bioavailability.
Recent studies have shown that recombinant human
growth hormone (GH) treatment accelerates growth
significantly in children with chronic renal insufficiency. 6,7
Preliminary reports of enhanced growth with GH
treatment in renal allograft patients are promising8 but it
has been suggested that GH might adversely effect graft
function.9 9
We report a 2-year, double-blind, dose-response trial of
GH in pubertal post-RTx patients with growth retardation
compared with non-GH-treated matched controls, during
which renal graft function was measured. The trial
compared 4 IU GH per m2 per day with 8 IU GH per m2 per
day in terms of growth, bone maturation, renal graft
function, plasma IGF-I and IGF-II, serum IGFBP-1 and
IGFBP-3, and other parameters.
Patients and methods
18 adolescent renal allograft recipients with growth retardation
were enrolled; 10 boys and 8 girls, aged 11-3&mdash;19-5 years with a mean
(standard deviation) age of 15-6 (2-3). Written informed consent
was obtained from patients and their parents. The study was
approved by the medical ethics committees of the participating
centres. Inclusion criteria were:  12 months after renal transplant;
stable without rejection episodes for at least 6 months; growth
retardation with a height standard deviation score (SDS) for
chronological age (HSDSCA) below - 1-88&deg; and a height velocity
(HV) for chronological age below the 50th percentile" or,
conversely, a HSDSCA above -1 88 and a HV below the 25th
percentile; prednisone dosage  0-25 mg per kg per day or 0 50 mg
per kg per alternate day for  6 months; normal concentration of
serum thyroid hormone and a normal acid-base balance; no history
of sex-hormone treatment; and no evidence of a cause for growth
retardation other than RTx. In two patients, a boy and a girl,
respectively aged 14 and 13-0 years with bone ages of 13 and
13 0, HSDSCA did fall below - 1-88, but their HV was slightly
1314
Treatment regimen
Group A Group B
GH 4 IU/m’ per day (0= 9) GH JU/M2 per day (n=7)
Sex 5 male, 4 female 4 male, 3 female
Age (yr) 155(26) 15 7 (19)
Bone age (yr) 126 (24) 12 3(20)
Pubertal stage:
early 5 5
late 4 2
Prednisone regimen
alternate-day 7 3
daily 2 4
Mean (SD) or number.
Table 1: Pretreatment clinical data for 16 dose-response study
patients
above the 50th percentile due to the onset of pubertal growth spurt
6 months previously. Their growth data were not included in
evaluation of the entire cohort, but were compared with
appropriate matched controls.
Immunosuppression was by prednisone (for all but 1 patient),
with either azathioprine (Aza) or cyclosporin A (CsA) or both. 10
patients received prednisone on alternate days (AD) and 7 daily
(D). To enable comparison, prednisone dosage was converted to a
daily dose in all calculations, amounting to a similar median dose
for AD and D patients of 015 mg per kg per day, with a range of
0-10-0-25. All but 1 patient had a cadaveric renal graft. 15 patients
underwent plasma GH and cortisol profile testing, for 10 of them
lasting 48 h and for 5, 24 h. The results of these tests are described
elsewhere.5
At enrolment and subsequently every 3 months, all patients were
examined by ACSH-K at participating centres. Height was
measured with a Harpenden stadiometer at the same time of day
and repeated until three consecutive readings were within 02 cm.
Patients were always weighed on the same scales. Pubertal stage
was determined according to Tanner, 12 whereby early puberty was
defined as Tanner stage 2/3 with signs of early pubertal growth
spurt and late puberty as Tanner 4/5 with declining growth at the
end of the growth spurt. Parental height served to calculate target
height for each patient individually, with the exception of one
adopted child. Secular trend was taken into account:
father’s + mother’s height + / - 12 cm /2, + 3 cm.
After stratification for pubertal stage, patients received one
subcutaneous injection per day (at bedtime) of biosynthetic GH
(Norditropin, Novo Nordisk A/S) in a dose of either 4 or 8 IU per
m2 body surface. 16 were randomly and blindly assigned to one or
the other dosage in an equal volume of a reconstituted preparation,
while the 2 patients who did not meet inclusion criterion were put
on 4 IU/m2 per day. Bone age was determined by the same
investigator according to Tanner-Whitehouse:12 radiographs of
left hand and wrist were taken at the start of the study and
subsequently every 6 months. Glomerular filtration rate (GFR
125I-Thalamate clearance test) and effective renal plasma flow
(ERPF) (1311-Hippuran test)13 expressed as mL/min per 1 73 m2
were measured at one participating centre (Sophia Children’s) at
the start of the study and after 2 and 12 months.
Blood and urine samples were taken at each examination for
blood cell count, serum electrolytes, urea-N, creatinine, calcium,
phosphate, and alkaline phosphatase; and urine glucose, protein,
blood, and sediment. Additional blood samples were taken at the
start of the study and subsequently every 6 months for other
analyses. After centrifugation, plasma samples were frozen
( - 20&deg;C) until assayed. Concentrations of plasma IGF-I and
IGF-II were determined by a specific radioimmunoassay after acid
chromatography." Methods used for quantifying IGF-binding
protein-1 and -3 (IGFB-1 and -3) are described elsewhere. 15
Concentrations of IGFs and IGF-binding proteins were
transformed to SDS for bone age (SDSBA). Concentrations of
plasma parathyroid hormone were measured with a two-step
immunochemical method.16
Figure: Growthcharts of 4 pubertal renal allograft recipients
who received GH
Dashed lines= bone age, black bar= period of growth hormone therapy,
HD = start of haemodialysis, Tx= renal transplantation, I=target height
+ / - 4 cm, P = O, start of puberty (Tanner stage M2), M = menarche,
G=+ testicular volume in mL.
Height was expressed as SDS for chronological age (hSDSCA),
ie, compared with Dutch reference data" and in cm. We did a
multiple regression analysis with the 1-year increment in height
(cm) in order to evaluate the influence of various variables on
height gain during GH treatment. In addition, we compared the
1-year and 2-year height increment of our GH-treated patients to
that of a matched control group. For each GH-treated patient,
controls were selected who would have been included in our GH
trial if this had been conducted at that time. They were selected
from a group of 149 patients who had their first RTx before the age
of 15 during the last decade and who had never received GH’ and
matched on sex, chronological age, pubertal stage, time elapsed
from RTx, immunosuppressive drug regimen, and retrospective
fulfillment of all inclusion criteria of the GH trial. The two
additional patients were compared with matched controls whose
prestudy HV had likewise been above the 50th percentile for 6
months.
In addition to GFR and ERPF determination during the first
year of the trial, we also determined the GFR for each year of the
study separately, by a height/plasma formula.17 As there was no
significant difference between the mean calculated GFR and the
mean measured GFR during the first study in the GH-treated .
patients, we compared their calculated results with those of
controls. The GFR at the start of the study period was divided into
3 strata: > 70 mL/min per 1 -73 M2 ; 40-70 mL/min per 1 73 M2 ; and
< 40 mL/min per 1-73mz.
Deterioration of renal graft function was considered to be
substantial when GFR was reduced by >25% during the study
period. When a patient returned to dialysis or received another
RTx, the GFR was considered to be < 10 mL/min per 1 73 m2 for
the rest of the study. Statistical analysis was by TS who alone knew
the code of the assignment to dosage group to this day. The
double-blind, dose-response design of the study will continue until
all patients have reached final height, unless safety problems
appear in relation to either GH dosage. Paired t-test was used for
differences within each dosage group, and the Student two-sample
t-test for differences between groups. Comparison of the incidence
of a GFR reduction >25% during the study period between
GH-treated patients and non-GH-treated controls was done by
conditional logistic regression analysis.
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Treatment regimen Change from
&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash; prestudy/start
Group A Group B A vs B
GH 4 IU/m2 GH 8 IU/m’ p
perday(n=9) perday(n=7)
Height Increment (cm)
Prestudy year 2 1(10) 2 3(15)
Yr0-1 8 8 (3 0)&dagger; 10 1 (2 4)&dagger; ns
Yr0-2* 148(67) 150(44) ns
Helght SDSCA
At start -35(15) -41(12)
AtlYr -28(16)t -31(10)t ns
At 2 Yr* -20(18)t -2 6 (1 4)t ns
&Dgr;BA/&Dgr;CA (Yr/Yr)
Yr1 08(05) 08(08) ns
Yr2* 09(07) 08(08) ns
hSDSCA= height standard deviation score for chronological age; BA= bone age;
CA=chronological age; *Group A (n= 7); Group B (n=5);tp<0 0 001 compared with prestudy
year; &Dagger;p< 0 05 compared with prestudy year. ns= not significant.
Table 2: Mean (SD) height increment, height SDSCA and
advance in bone maturation (ABA/ACA)
Results
Table 1 shows comparable pretreatment data for the 16
dose-response study patients. 3 patients did not complete
the 2-year study period: 2 resumed dialysis (after 15 and 16
months, respectively) while the third was a late entrant to
the study, completing a follow-up of 18 months.
Individual growth charts of 4 patients are shown in the
figure. Due to the double-blinded design and ongoing
nature of the study, GH doses are not shown. Table 2 shows
the effect of 2 different doses of GH on the height increment
and hSDSCA, and bone maturation in all patients. Mean
height increment was significantly greater during both the
first and second year of the GH study (p <0-001 and < 0-05,
respectively). Similarly, there was a significant increase in
mean hSDSCA after two years of GH (p < 0-01). However,
there was no significant difference for any of these growth
parameters between the patients who received 4 IU and 8
IU GH per m2 per day. The mean (SD) height increment
during 2 years of GH therapy was 14 8 (6-7) cm in group A
and 15-0 (4-4) cm in group B. Bone maturation was not
accelerated by GH treatment and was similar for both
groups.
To evaluate the influence of variables on height gain
during GH treatment, we did a multiple regression analysis
with the 1-year increment in height (cm) as the dependent
variable. Independent variables were: GH dose, pubertal
stage, prestudy HV (cm), and prednisone dose. Early
puberty (Tanner stage 2/3) was associated with a
significantly higher increment in height (p = 0-0001), the
difference with late puberty being 4-6 cm, provided the
other factors are equal. The higher GH dose was associated
with a slightly higher increment in 1-year height of 0 6 cm,
which was not significant (95% confidence interval, - 1-3
to 2-5 cm). Nor did prestudy HV or alternate-day vs daily
prednisone have a significant influence on the increment in
height during 1 year of GH.
16 GH-treated patients had from 2 to 4 (mean 3) matched
controls each for comparison of height increment over 1
year, while 14 had matched controls over 2 years. The mean
(SD) increment in height in GH-treated patients was
significantly higher than in matched controls: 10-0 (2-3) vs
3-4 (1-7) cm over 1 year (p < 0-0001) and 15-7 (5-1) vs 5-8
(3-4) cm over 2 years (p < 0-0001).
Two girls had one episode of acute rejection confirmed
by biopsy, respectively 7 and 15 months after the start of
GH, 19 and 60 months after the first RTx. For one, the dose
of prednisone and cyclosporin had been reduced during the
weeks before the event. They responded well to anti-
rejection treatment and continued GH. Two boys had
deterioration of renal function, respectively 11 and 12
months after starting GH, 30 and 40 months after their
second RTx. One of them had not complied with
immunosuppressive drugs, the other had hepatitis-C and
herpes infection, and his daily dose of azathioprine was less
than 1 mg/kg. This patient stopped GH when repeated
anti-rejection courses did not succeed, but the decline in
GFR continued as before. Both patients resumed dialysis.
Another boy (36 months after the first RTx) had a constant
GFR until he stopped taking immunosuppressive drugs for
almost 2 months (from 13-15 months after start of GH),
which resulted in a >25% decline in GFR despite anti-
rejection treatment. GH was continued and GFR stabilised.
GFR and ERPF were measured in 14 dose-response
study patients (8 group A, 6 group B). Two boys were not
tested after 12 months because of end-stage renal failure
(see above). For that reason, their GFR was set at 10
mL/min per 1 73 m2 for analysis. There was no significant
decline in mean GFR over 1 year of GH in either group.
Mean (SD) GFR for group A at the start, at 2, and at 12
months of GH was: 66 (12), 72 (15), 64 (25); and for group B:
67 (18), 76 (15), 60 (33) mL/min per 1.73m2. Likewise, there
was no significant change in ERPF during 1 year in either
dosage group. The mean (SD) ERPF for group A at the
start, at 2, and at 12 months was: 304 (70), 301 (80), 311 (82);
and for group B: 268 (73), 284 (70), 260 (86) mL/min per
1.73m2.
7 of 18 GH patients (39%) had a > 25% decline in GFR
during 2 years of GH treatment compared with 29 out of 90
controls (32%). There was therefore no significant
difference in the incidence of renal-graft deterioration
between GH-treated and non-GH-treated patients
(p = 0-97). Evaluation of factors possibly associated with the
>25% decline in graft function showed no difference
between a GH dose of 4 or 8 IU per m2 per day (Fisher exact
test, p = 1 -00). However, we found a trend towards a
negative influence of alternate-day prednisone on renal
function during GH therapy (Fisher exact test, p=0 15):
only 1 of 7 patients on daily prednisone had a > 25% decline
in graft function in contrast to 6 of 11 patients who received
alternate-day prednisone.
The mean (SD) pre-treatment IGF-I concentration
expressed as SDS for bone age (SDSBA) was within normal
for groups A and B, (0-1 [1-0] and 05 [1’4], respectively)
(table 3). This concentration increased significantly during
the first year of GH (p<0-0001) in both groups and
continued to increase significantly during the second year
(p < 0-0001) (data not shown). There was no statistical
difference in the GH-induced increment in IGF-I between
the groups. No correlation was found between either the
IGF-I SDSBA at the start or its change and the change in
height SDS for chronological age during 1 year of GH. The
mean (SD) plasma IGF-II concentration, expressed as
SDSBA, at the start of the study was within the normal
range for groups A and B, amounting to 0-7 (10) and 0-7
(0-8), respectively. GH induced a similar significant
decrease in the IGF-11 SDSBA in both groups (p<0-01)
(table 3).
The serum concentration of IGFBP-3 was raised at the
start of the study in both groups (mean [SD] SDSBA = 3 -0
[1’2] and 3-2 [1-3], respectively) and this increased
significantly during GH treatment in group A and B
(p < 00001). Prestudy IGFBP-1 concentrations were raised
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Treatment regimen
Group A Group B
GH 4IU/m’ per day (n = 9) GH 8 IU/m2 per day (n 7)
Start 1 year Start 1 year
IGF-I
ng/mL 279(102) 529 (136)* 316(70) 576 (11)*
SDSBA 01(10) 29(20)* 05(14) 24(11)*
IGF.1f
ng/mL 837(136) 694 (213)t 816(109) 694 (166)t
SDSBA 07(10) - 0 2 (1 3)t 07(08) - 0 2 (1 1)t
IGFBP-1 ,
ng/mL 38(13) 24(12) 32(15) 40(29)
SDSBA 20(24) 12(19) 2 4(22) 3 7 (4 3)
IGFBP-3
ng/mL 6404(1743) 9627(2193)* 6964(2274) 9137(1730)*
SDSBA 30(12) 4 8 (1 4)* 3 2 (1 3) 4 3 (0 9)*
IGF=insu I in-like growth factors. IGFBP=IGF-bndmg protein; SDSBA=standard deviation score
for bone age; *=p<0 0001 compared to start of study; &dagger;=p<0 01 compared to start of
study.
Table 3: Mean (SD) plasma concentrations of IGF and IGF-
binding proteins
in both groups (mean SDSBA=2.9 [2-4] and 2-4 [2-2],
respectively) and did not change significantly during GH
treatment (table 3). There was a significant negative
correlation between GFR at the start and serum IGFBP-1
SDSBA (r=-0-65; p<0-01) and IGFBP-3 SDSBA
(r= -046; p=0’03). No correlation was found between
pre-treatment concentrations of IGFBP-1 or IGFBP-3 and
the change in hSDSCA before or during the study; nor did
changes in IGF-binding proteins correlate with the growth
response or the GFR during GH therapy. The effect of 1 yr
of GH was substantially greater on the increment of IGF-I
than on the increment of IGFBP-3 (delta SDSBA = + 2 3 vs
+ 1 4, respectively). Comparable results were found for the
9 patients whose GFR remained above 50 mL/min per 1 73
mz over 2 yr of GH treatment (SDSBA = + 2-8 vs +17,
respectively).
Thyroid function was normal for all patients at the start
and remained so during the study. Mean (SD) serum
alkaline phosphatase increased significantly during the first
6 months of GH from 209 (83) to 264 (91) mMol/L
(p = 0-03), without a significant difference between group A
and B. There was no significant change in the parathyroid
hormone concentrations during GH regardless of dosage.
Discussion
This study shows that biosynthetic GH gives an impressive
increment in height and height SDScA in adolescents with
growth retardation after RTx at 4 or 8 GH IU/m2 per day.
These results contrast with reports that GH after renal
transplant is less effective in pubertal than in prepubertal
children.18 The GH-induced increment in height was
significantly higher in the children at an early pubertal stage
compared with those at a late pubertal stage. However, even
patients who were nearing completion of puberty had a
marked increase in height.
Effects of GH are more difficult to evaluate during
puberty. A placebo-controlled study would only provide
valuable data if patients were matched and paired before the
start of the study on the basis of several variables, including
pubertal stage, which is unlikely to be feasible. As an
alternative, we compared 2-year height increment of our
GH-treated patient group with that of a non-GH treated
patient group who were matched retrospectively. In
accordance with the above findings, the 2-year growth of
our GH-treated patients proved to be significantly greater
than that of the matched controls. During 2 years of GH
treatment, bone maturation did not accelerate with either
dose; on the contrary, bone age in some patients advanced
less than expected. Our results indicate that GH may well
improve final height of pubertal patients with short stature
after RTx, even in patients with advanced pubertal stage.
One major concern of GH treatment is its possible action
on renal graft function, either the risk of acute rejection
crises or progressive deterioration of function. If GH
reverses the catabolic effects of prednisone,19 it might also
modulate its immunosuppressive effects, whereas
permanent hyperfiltration might produce glomerular
sclerosis and thereby accelerate progression of renal graft
destruction.2O During 2 years of GH, only 2 out of 18
patients had one episode of biopsy-proven acute rejection, a
number no different from that occurring in the non-GH-
treated control group. Although 3 patients had progressive
graft deterioration during GH treatment, a direct relation
with GH seems unlikely since there were other reasons for
deterioration.
We measured the effect of GH on GFR and ERPF by
accurate methods. It appeared that 1 year of GH did not
result in a change in mean GFR. In addition, no significant
change in mean ERPF occurred. Many patients showed a
gradual increase in serum creatinine during the first 6
months of GH not associated with rejection, and GFR
showed stable graft function in most patients. GH
reportedly increases muscle mass whilst reversing
prednisone-induced catabolism;19 increased serum
creatinine probably reflects increased muscle mass due to
GH. The number of GH-treated patients with >25%
decline in GFR was not significantly different from the
number found in non-GH-treated matching controls. As
our control group was matched for immunosuppressive
treatment, changes in drug regimens can not have
influenced the results.
The most striking finding was that 6 of 11 patients (55%)
receiving alternate-day prednisone during GH therapy had
a > 25 % decline in renal function in contrast with only 1 out
of 7 patients (14%) on daily prednisone. Several studies in
non-GH treated patients have reported that alternate-day
prednisone had reduced growth-depressing effects,2’
although most investigators concluded this regimen was not
associated with increased risk of rejection.22 Only one
author reported a higher incidence of rejection in non-GH
treated patients on alternate-day prednisone.23 It may be
that GH stimulates the immune system on the prednisone-
free day, thus precipitating progressive graft deterioration.
Pretreatment plasma IGF-I concentrations were normal
for patients receiving either GH dose, in agreement with
findings in other RTx patients.3 Pretreatment
concentrations of serum IGF-binding protein-3 (IGFBP-
3) were significantly increased, resembling the findings in
growth-retarded children with chronic renal insufficiency
(CRI).6 GH treatment induced a significant increase in
serum concentrations of GH-dependent IGF-I and to a
lesser degree IGFBP-3. Pretreatment plasma
concentration of IGF-II were normal and GH induced a
significant decrease in mean levels, regardless of dosage.
Pretreatment serum IGFBP-1 concentrations were raised
in all patients, but not to the degree that we found in
growth-retarded children with CRI.5 In CRI patients, GH
induced a significant decrease in serum IGFBP-1
concentrations, but did not change significantly during GH
treatment in the post-RTx patients. Before the start of GH
there was a significant inverse correlation between the
IGFBP-3, IGFBP-1, and graft GFR which disappeared
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with GH. Excess of serum IGFBP-3 causes a decrease in
IGF-bioactivity.24 In addition, in-vivo IGF bioassays show
an inhibitory effect of the small-molecular-weight IGFBP-
1 on IGF-stimulated biogenesis and cell metabolism.25
Thus, it may be that reduced graft function together with
raised concentrations of IGFBP’s and decreased IGF-
bioavailability are involved in growth retardation after
RTx.
Prednisone treatment is believed to be mainly
responsible for growth retardation after RTx. Alternate-
day prednisone was found to reduce but not eliminate
growth retardation.26 Prednisone-induced inhibition of
local IGF-I gene expression and inhibition of GH secretion
might be mechanisms of growth retardation.27-29
Significantly improved growth during GH may have been
due to the positive effect of GH on IGF-I and improved
bioavailability coupled with the direct growth-promoting
effect on target tissues,30 thus confirming animal studies
which show that the growth-depressing effects of
corticosteroids can be overcome by GH.19 Serum alkaline
phosphatase concentration increased significantly during
the first 12 months of GH, but there was no radiological
signs of renal osteodystrophy, so the increase may be due to
osteoblastic activity resulting from GH.
2 years of GH in a dose of either 4 or 8 IU per m2 per day
results in a significant and sustained improvement of height
in pubertal patients with growth retardation after RTx. As
there was no acceleration in bone maturation, GH may well
improve the final height of these patients. Although a small
number of patients had progressive deterioration of graft
function, we could not find a relation with GH treatment.
In view of the difference in graft deterioration observed
between patients on alternate-day and those on daily
prednisone therapy, it seems worthwhile to investigate the
optimal prednisone regimen for the duration of GH
therapy.
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